These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37675002)

  • 1. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
    Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
    Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
    Tsung I; Worden FP; Fontana RJ
    Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
    Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
    J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
    Paoluzzi L; Ow TJ
    Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report.
    Geidel G; Rünger A; Schneider SW; Gebhardt C
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():49-52. PubMed ID: 34855252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
    O'Connell KA; Schmults CD
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
    Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D
    J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
    Front Oncol; 2021; 11():691980. PubMed ID: 34540666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
    Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma.
    De Falco V; Napolitano S; Franco R; Zito Marino F; Formisano L; Esposito D; Suarato G; Napolitano R; Esposito A; Caraglia F; Giugliano MC; Cioli E; Famiglietti V; Bianco R; Argenziano G; Ronchi A; Ciardiello D; Nardone V; D'Ippolito E; Del Tufo S; Ciardiello F; Troiani T
    Oncoimmunology; 2024; 13(1):2388315. PubMed ID: 39206096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
    Mager L; Gardeen S; Carr DR; Shahwan KT
    Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
    Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.